Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis (Q36602782)

15 August 2017

1 reference

title

Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis (English)

1 reference

15 August 2017

Ales Dudesek

1

1 reference

15 August 2017

Uwe K Zettl

series ordinal

2

1 reference

15 August 2017

language of work or name

1 reference

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

253 Suppl 5

1 reference

15 August 2017

page(s)

V50-8

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-006-5007-x

15 August 2017

exact match

0 references

cites work

Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-5007-X

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-5007-X

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-5007-X

IV immunoglobulin does not reverse established weakness in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-5007-X

Immunoglobulins reactive with myelin basic protein promote CNS remyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-5007-X

IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-5007-X

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-006-5007-X

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

21 January 2018

1 reference

12 December 2020

Immunopathology of secondary-progressive multiple sclerosis.

1 reference

12 December 2020

Antibody-mediated remyelination: relevance to multiple sclerosis.

1 reference

12 December 2020

Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis -- outline of a double-blind randomized, placebo-controlled trial.

1 reference

12 December 2020

Spontaneous remyelination following extensive demyelination is associated with improved neurological function in a viral model of multiple sclerosis

1 reference

12 December 2020

Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.

1 reference

12 December 2020

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study

1 reference

12 December 2020

Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

The role of qualitative and quantitative MRI assessment of multiple sclerosis lesions according to their in evaluating the efficacy of intravenous immunoglobulin G.

1 reference

12 December 2020

A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group

1 reference

12 December 2020

Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis

1 reference

12 December 2020

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

12 December 2020

Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002

1 reference

12 December 2020

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

1 reference

12 December 2020

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

12 December 2020

First results of immunotherapy with immunoglobulin G in multiple sclerosis patients

1 reference

12 December 2020

Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis--results of a retrospective multicenter observational study over five years

1 reference

12 December 2020

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

1 reference

12 December 2020

Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis

1 reference

12 December 2020

A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

12 December 2020

Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.

1 reference

12 December 2020

Intravenous gamma globulin in progressive MS

1 reference

12 December 2020

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

12 December 2020

Early onset multiple sclerosis

1 reference

12 December 2020

[Therapy of multiple sclerosis with immunoglobulin G]

1 reference

12 December 2020

1 reference

12 December 2020

Immunoglobulins promote remyelination in the central nervous system

1 reference

12 December 2020

Axonal transection in the lesions of multiple sclerosis

1 reference

12 December 2020

A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis

1 reference

12 December 2020

[Use of i.v. immunoglobulins in neurology. Evidence-based consensus]

1 reference

12 December 2020

Qualitative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: preliminary report

1 reference

12 December 2020

Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system

1 reference

12 December 2020

Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis

1 reference

12 December 2020

[MS Therapy Consensus Group. Immunomodulating staged therapy of multiple sclerosis]

1 reference

12 December 2020

10.1007/S00415-006-5007-X

Identifiers

DOI

1 reference

15 August 2017

1 reference